Is Helicobacter pylori a WHO Class I Carcinogen?

The updated guidelines include 19 recommendations related to the diagnosis and management of eosinophilic esophagitis.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

Your daily dose of the clinical news you may have missed.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.